Homocysteine: a new cardiac risk factor?
Elevated plasma homocysteine levels have recently been implicated as a new risk factor for coronary artery disease. In this article, homocysteine metabolism, secondary causes of elevated plasma homocysteine, and the potential mechanism of vascular damage in hyperhomocysteinemia are briefly reviewed. The current clinical evidence implicating hyperhomocysteinemia as a risk factor for coronary artery disease, as well as the data regarding the effects of B vitamin supplementation on homocysteine concentrations, are also reviewed. The current recommendation of the authors is to treat patients with known coronary artery disease or those who are considered to be at high risk for coronary artery disease with 400 microg of folate supplementation. Until prospective clinical trial data become available, this approach appears to be a safe and effective way to approach this patient population.
Chai
A U
AU
Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, USA.
Abrams
J
J
D003324:Coronary Artery Disease / Q000209:etiology / Q000517:prevention & control; D003327:Coronary Disease / Q000209:etiology*; D019587:Dietary Supplements; D005492:Folic Acid / Q000627:therapeutic use; D006710:Homocysteine / Q000378:metabolism*; D006801:Humans; D020138:Hyperhomocysteinemia / Q000150:complications* / Q000209:etiology / Q000628:therapy; D008954:Models, Biological; D012307:Risk Factors
D006710:Homocysteine; D005492:Folic Acid